Cargando…
Pharmacovigilance in juvenile idiopathic arthritis patients (Pharmachild) treated with biologic agents and/or methotrexate. Consolidated baseline characteristics from Pharmachild and other national registries
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4184298/ http://dx.doi.org/10.1186/1546-0096-12-S1-P7 |
| _version_ | 1782337821743251456 |
|---|---|
| author | Swart, Joost Consolaro, Alessandro Horneff, Gerd Hyrich, Kimme L Bovis, Francesca Melo-Gomes, Jose Alexeeva, Ekaterina Lanni, Stefano Ganser, Gerd Panaviene, Violeta Anton, Jordi Foeldvari, Ivan Stanevicha, Valda Nielsen, Susan Trauzeddel, Ralf Ailioaie, Constantin Quartier, Pierre Hospach, Toni Susic, Gordana Trachana, Maria Weller-Heinemann, Frank Martini, Alberto Wulffraat, Nico Ruperto, Nicolino |
| author_facet | Swart, Joost Consolaro, Alessandro Horneff, Gerd Hyrich, Kimme L Bovis, Francesca Melo-Gomes, Jose Alexeeva, Ekaterina Lanni, Stefano Ganser, Gerd Panaviene, Violeta Anton, Jordi Foeldvari, Ivan Stanevicha, Valda Nielsen, Susan Trauzeddel, Ralf Ailioaie, Constantin Quartier, Pierre Hospach, Toni Susic, Gordana Trachana, Maria Weller-Heinemann, Frank Martini, Alberto Wulffraat, Nico Ruperto, Nicolino |
| author_sort | Swart, Joost |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-4184298 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2014 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-41842982014-10-30 Pharmacovigilance in juvenile idiopathic arthritis patients (Pharmachild) treated with biologic agents and/or methotrexate. Consolidated baseline characteristics from Pharmachild and other national registries Swart, Joost Consolaro, Alessandro Horneff, Gerd Hyrich, Kimme L Bovis, Francesca Melo-Gomes, Jose Alexeeva, Ekaterina Lanni, Stefano Ganser, Gerd Panaviene, Violeta Anton, Jordi Foeldvari, Ivan Stanevicha, Valda Nielsen, Susan Trauzeddel, Ralf Ailioaie, Constantin Quartier, Pierre Hospach, Toni Susic, Gordana Trachana, Maria Weller-Heinemann, Frank Martini, Alberto Wulffraat, Nico Ruperto, Nicolino Pediatr Rheumatol Online J Poster Presentation BioMed Central 2014-09-17 /pmc/articles/PMC4184298/ http://dx.doi.org/10.1186/1546-0096-12-S1-P7 Text en Copyright © 2014 Swart et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| spellingShingle | Poster Presentation Swart, Joost Consolaro, Alessandro Horneff, Gerd Hyrich, Kimme L Bovis, Francesca Melo-Gomes, Jose Alexeeva, Ekaterina Lanni, Stefano Ganser, Gerd Panaviene, Violeta Anton, Jordi Foeldvari, Ivan Stanevicha, Valda Nielsen, Susan Trauzeddel, Ralf Ailioaie, Constantin Quartier, Pierre Hospach, Toni Susic, Gordana Trachana, Maria Weller-Heinemann, Frank Martini, Alberto Wulffraat, Nico Ruperto, Nicolino Pharmacovigilance in juvenile idiopathic arthritis patients (Pharmachild) treated with biologic agents and/or methotrexate. Consolidated baseline characteristics from Pharmachild and other national registries |
| title | Pharmacovigilance in juvenile idiopathic arthritis patients (Pharmachild) treated with biologic agents and/or methotrexate. Consolidated baseline characteristics from Pharmachild and other national registries |
| title_full | Pharmacovigilance in juvenile idiopathic arthritis patients (Pharmachild) treated with biologic agents and/or methotrexate. Consolidated baseline characteristics from Pharmachild and other national registries |
| title_fullStr | Pharmacovigilance in juvenile idiopathic arthritis patients (Pharmachild) treated with biologic agents and/or methotrexate. Consolidated baseline characteristics from Pharmachild and other national registries |
| title_full_unstemmed | Pharmacovigilance in juvenile idiopathic arthritis patients (Pharmachild) treated with biologic agents and/or methotrexate. Consolidated baseline characteristics from Pharmachild and other national registries |
| title_short | Pharmacovigilance in juvenile idiopathic arthritis patients (Pharmachild) treated with biologic agents and/or methotrexate. Consolidated baseline characteristics from Pharmachild and other national registries |
| title_sort | pharmacovigilance in juvenile idiopathic arthritis patients (pharmachild) treated with biologic agents and/or methotrexate. consolidated baseline characteristics from pharmachild and other national registries |
| topic | Poster Presentation |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4184298/ http://dx.doi.org/10.1186/1546-0096-12-S1-P7 |
| work_keys_str_mv | AT swartjoost pharmacovigilanceinjuvenileidiopathicarthritispatientspharmachildtreatedwithbiologicagentsandormethotrexateconsolidatedbaselinecharacteristicsfrompharmachildandothernationalregistries AT consolaroalessandro pharmacovigilanceinjuvenileidiopathicarthritispatientspharmachildtreatedwithbiologicagentsandormethotrexateconsolidatedbaselinecharacteristicsfrompharmachildandothernationalregistries AT horneffgerd pharmacovigilanceinjuvenileidiopathicarthritispatientspharmachildtreatedwithbiologicagentsandormethotrexateconsolidatedbaselinecharacteristicsfrompharmachildandothernationalregistries AT hyrichkimmel pharmacovigilanceinjuvenileidiopathicarthritispatientspharmachildtreatedwithbiologicagentsandormethotrexateconsolidatedbaselinecharacteristicsfrompharmachildandothernationalregistries AT bovisfrancesca pharmacovigilanceinjuvenileidiopathicarthritispatientspharmachildtreatedwithbiologicagentsandormethotrexateconsolidatedbaselinecharacteristicsfrompharmachildandothernationalregistries AT melogomesjose pharmacovigilanceinjuvenileidiopathicarthritispatientspharmachildtreatedwithbiologicagentsandormethotrexateconsolidatedbaselinecharacteristicsfrompharmachildandothernationalregistries AT alexeevaekaterina pharmacovigilanceinjuvenileidiopathicarthritispatientspharmachildtreatedwithbiologicagentsandormethotrexateconsolidatedbaselinecharacteristicsfrompharmachildandothernationalregistries AT lannistefano pharmacovigilanceinjuvenileidiopathicarthritispatientspharmachildtreatedwithbiologicagentsandormethotrexateconsolidatedbaselinecharacteristicsfrompharmachildandothernationalregistries AT gansergerd pharmacovigilanceinjuvenileidiopathicarthritispatientspharmachildtreatedwithbiologicagentsandormethotrexateconsolidatedbaselinecharacteristicsfrompharmachildandothernationalregistries AT panavienevioleta pharmacovigilanceinjuvenileidiopathicarthritispatientspharmachildtreatedwithbiologicagentsandormethotrexateconsolidatedbaselinecharacteristicsfrompharmachildandothernationalregistries AT antonjordi pharmacovigilanceinjuvenileidiopathicarthritispatientspharmachildtreatedwithbiologicagentsandormethotrexateconsolidatedbaselinecharacteristicsfrompharmachildandothernationalregistries AT foeldvariivan pharmacovigilanceinjuvenileidiopathicarthritispatientspharmachildtreatedwithbiologicagentsandormethotrexateconsolidatedbaselinecharacteristicsfrompharmachildandothernationalregistries AT stanevichavalda pharmacovigilanceinjuvenileidiopathicarthritispatientspharmachildtreatedwithbiologicagentsandormethotrexateconsolidatedbaselinecharacteristicsfrompharmachildandothernationalregistries AT nielsensusan pharmacovigilanceinjuvenileidiopathicarthritispatientspharmachildtreatedwithbiologicagentsandormethotrexateconsolidatedbaselinecharacteristicsfrompharmachildandothernationalregistries AT trauzeddelralf pharmacovigilanceinjuvenileidiopathicarthritispatientspharmachildtreatedwithbiologicagentsandormethotrexateconsolidatedbaselinecharacteristicsfrompharmachildandothernationalregistries AT ailioaieconstantin pharmacovigilanceinjuvenileidiopathicarthritispatientspharmachildtreatedwithbiologicagentsandormethotrexateconsolidatedbaselinecharacteristicsfrompharmachildandothernationalregistries AT quartierpierre pharmacovigilanceinjuvenileidiopathicarthritispatientspharmachildtreatedwithbiologicagentsandormethotrexateconsolidatedbaselinecharacteristicsfrompharmachildandothernationalregistries AT hospachtoni pharmacovigilanceinjuvenileidiopathicarthritispatientspharmachildtreatedwithbiologicagentsandormethotrexateconsolidatedbaselinecharacteristicsfrompharmachildandothernationalregistries AT susicgordana pharmacovigilanceinjuvenileidiopathicarthritispatientspharmachildtreatedwithbiologicagentsandormethotrexateconsolidatedbaselinecharacteristicsfrompharmachildandothernationalregistries AT trachanamaria pharmacovigilanceinjuvenileidiopathicarthritispatientspharmachildtreatedwithbiologicagentsandormethotrexateconsolidatedbaselinecharacteristicsfrompharmachildandothernationalregistries AT wellerheinemannfrank pharmacovigilanceinjuvenileidiopathicarthritispatientspharmachildtreatedwithbiologicagentsandormethotrexateconsolidatedbaselinecharacteristicsfrompharmachildandothernationalregistries AT martinialberto pharmacovigilanceinjuvenileidiopathicarthritispatientspharmachildtreatedwithbiologicagentsandormethotrexateconsolidatedbaselinecharacteristicsfrompharmachildandothernationalregistries AT wulffraatnico pharmacovigilanceinjuvenileidiopathicarthritispatientspharmachildtreatedwithbiologicagentsandormethotrexateconsolidatedbaselinecharacteristicsfrompharmachildandothernationalregistries AT rupertonicolino pharmacovigilanceinjuvenileidiopathicarthritispatientspharmachildtreatedwithbiologicagentsandormethotrexateconsolidatedbaselinecharacteristicsfrompharmachildandothernationalregistries |